Sarcopenia , as defined by reduced muscle mass alone , was found to be very prevalent in patients with lung cancer , regardless of body mass index , and where present was associated with poorer functional status and overall survival .
The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results .
There are very limited data on the correlation between degree of sarcopenia and muscle function , which has a non-linear relationship in older non-cancer population s. CONCLUSIONS Loss of muscle mass is a significant contributor to morbidity in patients with lung cancer .
OBJECTIVES There is growing awareness of the relationship between sarcopenia ( loss of muscle mass and function ) , and outcomes in cancer , making it a potential target for future therapies .
In order to inform future research and practice , we undertook a systematic review of factors associated with loss of muscle mass , and the relationship between muscle function and muscle mass in lung cancer , a common condition associated with poor outcomes .
Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients.
The authors examined the effect of recombinant-human growth hormone ( r-hGH ) and insulin ( INS ) administration on protein kinetics in cancer patients . Twenty-eight cancer patients either received r-hGH for 3 days ( GH group , n = 12 , weight loss = 6 + /- 2 % ) or were not treated ( control [ CTL ] group , n = 16 , weight loss = 11 + /- 2 % ) before metabolic study . Recombinant-human growth hormone dose was 0.1 mg/kg/day ( n = 6 ) or 0.2 mg/kg/day ( n = 6 ) . Patients then underwent measurement of baseline protein kinetics ( GH/B , CTL/B ) followed by a 2-hour euglycemic insulin infusion ( 1 mU/kg/minute ) and repeat kinetic measurements ( GH/INS , CTL/INS ) . Whole-body protein net balance ( mumol leucine/kg/minute ) was higher ( p less than 0.05 ) in GH/INS ( 0.20 + /- 0.06 ) than in CTL/INS ( 0.06 + /- 0.03 ) or GH/B ( -0.19 + /- 0.03 ) . Skeletal muscle protein net balance ( nmol phenylalanine/100 g/minute ) in GH/INS ( 25 + /- 6 ) and CTL/INS ( 19 + /- 5 ) was higher than CTL/B ( -18 + /- 3 ) . Recombinant-human growth hormone and insulin reduce whole-body and skeletal muscle protein loss in cancer patients . Simultaneous use of these agents during nutritional therapy may benefit the cancer patient
Sarcopenia , as defined by reduced muscle mass alone , was found to be very prevalent in patients with lung cancer , regardless of body mass index , and where present was associated with poorer functional status and overall survival .
The effect of nutritional supplements and ATP infusions on muscle mass showed conflicting results .
There are very limited data on the correlation between degree of sarcopenia and muscle function , which has a non-linear relationship in older non-cancer population s. CONCLUSIONS Loss of muscle mass is a significant contributor to morbidity in patients with lung cancer .
OBJECTIVES There is growing awareness of the relationship between sarcopenia ( loss of muscle mass and function ) , and outcomes in cancer , making it a potential target for future therapies .
In order to inform future research and practice , we undertook a systematic review of factors associated with loss of muscle mass , and the relationship between muscle function and muscle mass in lung cancer , a common condition associated with poor outcomes .